NDA 219935 · Sagent
Famotidine
Famotidine · Intravenous · Histamine-2 Receptor Antagonist
DiscontinuedLast checked: Nov 19, 2026Latest source record: Jul 16, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2025
Jul 16, 2025
Approved uses
1
Original approval plus efficacy supplements
Registered trials
147
23 Phase 3, 15 recruiting
FAERS reports
78,942
53,278 serious, 7,746 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jun 6, 2026.
Famotidine Injection is indicated for use in hospitalized adults, or as an alternative to oral famotidine in adults, for the treatment of: active duodenal ulcer (DU). active gastric ulcer (GU). symptomatic nonerosive gastroesophageal reflux disease (GERD). erosive esophagitis due to GERD, diagnosed by endoscopy. treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). reduction of the risk of duodenal ulcer recurrence. FAMOTIDINE Injection is a histamine-2 (H 2 ) receptor antagonist indicated: In hospitalized adults, or as an alternative to oral famotidine in adults, for the treatment of: active duodenal ulcer (DU). active gastric ulcer (GU). symptomatic nonerosive gastroesophageal reflux disease (GERD). erosive esophagitis due to GERD, diagnosed by endoscopy. treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). reduction of the risk of DU recurrence. In hospitalized pediatric patients 1 year of age and older, or as an alternative to oral famotidine in pediatric patients 1 year of age and older, for the treatment of: peptic ulcer disease. Pediatric Patients 1 Year of Age and Older Famotidine Injection is indicated in hospitalized pediatric patients 1 year of age and older, or as an alternative to oral famotidine in pediatric patients 1 year of age and older, for the treatment of peptic ulcer disease.
Mechanism: Famotidine is a competitive inhibitor of histamine H 2 -receptors. The primary clinically important pharmacologic activity of famotidine is inhibition of gastric secretion. Both the acid concentration and volume of gastric secretion are suppressed by famotidine, while changes in pepsin secretion are proportional to volume output.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
3 products under this application
- FAMOTIDINE · FAMOTIDINE 20MG/5ML (4MG/ML) · SOLUTION, INTRAVENOUS · Discontinued
- FAMOTIDINE · FAMOTIDINE 40MG/10ML (4MG/ML) · SOLUTION, INTRAVENOUS · Discontinued
- FAMOTIDINE · FAMOTIDINE 200MG/50ML (4MG/ML) · SOLUTION, INTRAVENOUS · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Famotidine" as an intervention, any sponsor and status, largest first.
- Prophylaxis for Aspiration of Gastric Contents.Pivotal-lookingCompleted
King Saud UniversityAcademic, hospital or other
NCT02703896 · 1,920 participants · Start Jan 2012 · Primary completion Jan 2012
Drug: Drug either PPIS or H2RA and prokinetics · For: Pulmonary Aspiration of Gastric Contents
- I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill PatientsPivotal-lookingActive, not recruiting
QuantumLeap Healthcare CollaborativeAcademic, hospital or other
NCT04488081 · 1,500 participants (planned) · Start Jul 31, 2020 · Primary completion Jul 31, 2028
Drug: Remdesivir; Imatinib Mesylate and 12 more · For: COVID-19
Sites: Birmingham, Alabama; Davis, California; Irvine, California · 36 sites in all
- Efficacy and Safety Study of HZT-501 in Subjects Requiring Nonsteroidal Anti-Inflammatory Drug (NSAID) TreatmentPivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT00450216 · 906 participants · Start Mar 2007 · Primary completion Aug 2008
Drug: Ibuprofen/famotidine; Ibuprofen · For: Ulcer
- Efficacy and Safety Study of HZT-501 in Reducing the Risk of Ibuprofen-associated UlcersPivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT00450658 · 627 participants · Start Mar 2007 · Primary completion Sep 2008
Drug: HZT-501; Ibuprofen · For: Peptic Ulcer
- Placebo Controlled Phase IV Study to Compare the Efficacy and Safety of a Single Dose of Oral Talcid, a Single Dose of Oral Famotidine and a Single Dose of Placebo in Patients With Acute Heartburn EpisodesPivotal-lookingCompleted
BayerBayer (BAYRY)
NCT01928888 · 559 participants · Start May 2003 · Primary completion Feb 2004
Drug: Talcid (Hydrotalcite, BAY4516H); Famotidine and 1 more · For: Heartburn
Sites: Frankfurt am Main, Germany; Dresden, Germany; Leipzig, Germany · 5 sites in all
- Prevention of Gastrointestinal Bleeding in Patients With Severe Ischemic Heart DiseasePivotal-lookingCompleted
Ruttonjee HospitalAcademic, hospital or other
NCT00683111 · 500 participants (planned) · Start Jul 2008 · Primary completion Dec 2011
Drug: esomeprazole 20 mg daily; famotidine 40 mg daily · For: Acute Coronary Syndrome; Acute Myocardial Infarction
Sites: Hong Kong, China
- A Multi-center, Randomized, Double-blind Phase III Clinical Trial to Assess and Compare to the Efficacy and Safety of Lafutidine, Famotidine and Omeprazole-referenced in Korean Erosive Esophagitis PatientsPivotal-lookingCompleted
Boryung Pharmaceutical Co., LtdIndustry
NCT01499368 · 495 participants · Start Nov 2011 · Primary completion Nov 2012
Drug: Lafutidine; Famotidine and 1 more · For: Erosive Esophagitis
- Famotidine in Subjects With Non-erosive Gastroesophageal Reflux DiseasePivotal-lookingCompleted
Astellas Pharma IncAstellas (ALPMY)
NCT00141960 · 480 participants · Start Sep 2005
Drug: Famotidine · For: Gastroesophageal Reflux
Sites: Hokkaido Region, Japan; Kanto Region, Japan; Kinki Region, Japan · 7 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- nausea5,149
- fatigue4,939
- diarrhoea4,819
- off label use4,129
- dyspnoea3,819
- drug ineffective3,758
- chronic kidney disease3,530
- headache3,502
- vomiting3,144
- pain3,086
- dizziness2,919
- acute kidney injury2,806
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 678 |
| 2005 | 672 |
| 2006 | 635 |
| 2007 | 628 |
| 2008 | 800 |
| 2009 | 663 |
| 2010 | 963 |
| 2011 | 1,476 |
| 2012 | 1,834 |
| 2013 | 1,084 |
| 2014 | 1,359 |
| 2015 | 2,195 |
| 2016 | 2,700 |
| 2017 | 3,026 |
| 2018 | 4,037 |
| 2019 | 4,683 |
| 2020 | 6,218 |
| 2021 | 6,355 |
| 2022 | 6,923 |
| 2023 | 7,023 |
| 2024 | 8,242 |
| 2025 | 9,224 |
| 2026 | 7,520 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Famotidine (Famotidine In NaCl,Iso-Osm/PF)
2024 spending
$663
Beneficiaries
56
90 claims
Per beneficiary
$12
$0.16 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $1,295 |
| 2021 | $912 |
| 2022 | $426 |
| 2023 | $846 |
| 2024 | $663 |
Part D: Famotidine (Famotidine/PF)
2024 spending
$74K
Beneficiaries
1,718
9,948 claims
Per beneficiary
$43
$0.48 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $63,762 |
| 2021 | $76,737 |
| 2022 | $74,809 |
| 2023 | $69,118 |
| 2024 | $73,581 |
Part D: Famotidine* (Famotidine)
2024 spending
$179M
Beneficiaries
3,926,510
14,044,674 claims
Per beneficiary
$46
$0.16 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $143,448,123 |
| 2021 | $200,948,982 |
| 2022 | $181,466,099 |
| 2023 | $202,809,307 |
| 2024 | $178,983,102 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Histamine receptors and COVID-19.
Ennis M, Tiligada K · Inflamm Res 2021 · Systematic Review
- Pharmacological interventions for prevention of weight gain in people with schizophrenia.
Agarwal SM, Stogios N, Ahsan ZA, et al. · Cochrane Database Syst Rev 2022 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Famotidine (Pepcid).
· Med Lett Drugs Ther 1987 · Clinical Trial
- Pharmacokinetics of famotidine in infants.
Wenning LA, Murphy MG, James LP, et al. · Clin Pharmacokinet 2005 · Clinical Trial, Multicenter Study
- Famotidine: effective treatment of Zollinger-Ellison syndrome.
Howard JM, Vinayek R, Maton PN, et al. · J Clin Gastroenterol 1987 · Clinical Trial, Comparative Study
- Hemodynamic status during famotidine infusion.
Heiselman DE, Chapman J, Malik M, et al. · DICP 1990 · Clinical Trial, Randomized Controlled Trial
Sponsor: Sagent
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.